Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Depakote ER Clear all
Not listed Phase 1 Interventional

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

NCT00197834
View directory record Official record
Conditions
Dementia
Interventions
Depakote
Drug
Lead sponsor
Hearthstone Alzheimer Care
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2006 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia

NCT00552500
View directory record Official record
Conditions
Insulin Resistance, Body Composition
Interventions
Depakote (valproate)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 4 Interventional

Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder

NCT00203528
View directory record Official record
Conditions
Substance Abuse, Bipolar Depression
Interventions
divalproex sodium ER, risperidone
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

NCT00088452
View directory record Official record
Conditions
Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions
Ethosuximide, Lamotrigine, Valproic acid
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
30 Months to 13 Years
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

NCT00195754
View directory record Official record
Conditions
Migraines
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2007 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine

NCT00195806
View directory record Official record
Conditions
Migraine
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 2, 2007 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents

NCT00195741
View directory record Official record
Conditions
Migraine
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

NCT01182285
View directory record Official record
Conditions
Thyroid Neoplasm
Interventions
Valproic Acid, Liothyronine Sodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions

NCT00834990
View directory record Official record
Conditions
Healthy
Interventions
divalproex sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

NCT03385525
View directory record Official record
Conditions
Drug Interaction
Interventions
BIIB074, Valproic Acid
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 4 Interventional

Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings

NCT02078596
View directory record Official record
Conditions
Irritable Aggression
Interventions
Divalproex
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
7 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 2, 2026, 5:39 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

NCT00375557
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions
Divalproex ER, Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

NCT01184391
View directory record Official record
Conditions
Healthy
Interventions
DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study

NCT01729598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

NCT00646711
View directory record Official record
Conditions
Pediatric Epilepsy
Interventions
Depakote Delayed-Release/Depakote Sprinkle, Depakote ER
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Sequential Multiple Assignment Treatment for Bipolar Disorder

NCT01588457
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
Lithium, Divalproex, Lamotrigine, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 2, 2026, 5:39 PM EDT
Completed No phase listed Observational

A Study to Look at Antiepileptic Drug Levels While on Lamictal or Depakote With or Without an Oral Contraceptive

NCT00296413
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 4 Interventional

Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder

NCT00199966
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex sodium extended release
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions

NCT00974441
View directory record Official record
Conditions
Healthy
Interventions
Divalproex Sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Sep 2, 2026, 5:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:

NCT00356018
View directory record Official record
Conditions
Epilepsy
Interventions
Compliance
Behavioral
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
16 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 2, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

NCT02068586
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
Interventions
Sunitinib, Valproic Acid, Sunitinib Malate, Sunitinib Malate + Valproic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 2Phase 3 Interventional

Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms

NCT00202514
View directory record Official record
Conditions
Alcoholism, Alcohol Related Disorders, Mood Disorders
Interventions
divalproex sodium extended release
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Valproate in Late Life Schizophrenia

NCT00194025
View directory record Official record
Conditions
Schizophrenia
Interventions
Valproate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Sep 2, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions

NCT00974012
View directory record Official record
Conditions
Healthy
Interventions
Divalproex Sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Sep 2, 2026, 5:39 PM EDT